Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

417P - EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project

Date

14 Sep 2024

Session

Poster session 15

Topics

Cancer Research

Tumour Site

Breast Cancer

Presenters

Claudia Omarini

Citation

Annals of Oncology (2024) 35 (suppl_2): S357-S405. 10.1016/annonc/annonc1579

Authors

C. Omarini1, V. Catani2, A. Toss3, I. Mastrolia2, F. Banchelli4, O. Ponzoni3, M. Brucale5, F. Valle5, M.C. Baschieri3, V. Masciale2, R. D'Amico4, F. Piacentini3, M. Dominici3

Author affiliations

  • 1 Oncology And Haematology Department, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 2 Laboratory Cellular Therapy, Department Of Medical And Surgical Sciences For Children & Adults, University of Modena and Reggio Emilia, Modena, Italy, 41121 - Modena MO/IT
  • 3 Dept. Of Medical And Surgical Sciences For Children And Adults, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 4 Unit Of Statistical And Methodological Support To Clinical Research, University of Modena and Reggio Emilia, Modena, Italy, 41121 - Modena MO/IT
  • 5 Area Della Ricerca Cnr Di Bologna, Consiglio Nazionale delle Ricerche e istituto per lo studio dei materiali Nanostrutturati ISMN, 40129 - Bologna/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 417P

Background

Emerging evidence highlights the key role of microRNA (miR)-21 in cell-to-cell communication and tumorigenesis. Limited knowledge exists on the expression and clinical meaning of miR-21 in extracellular vesicles (EVs) of breast cancer (BC) patients. Thus, the aim of this study has been to assess EV-derived miR-21 expression in different BC subsets.

Methods

One hundred women were enrolled: 30 with early BC, 30 with metastatic BC on treatment progression, 30 cancer survivors on follow up and 10 healthy controls matched for age and BMI. EVs, isolated from serum samples, were characterized by nanoparticle tracking analyzer (NTA), scanning electron microscopy (SEM) and atomic force microscopy (AFM) to detect their concentration, size and structure. The miR-21 in EVs was evaluated by Real Time PCR. The expression of miR-21 was compared between groups by calculating the ΔΔCt statistic and the fold change, considering miR-16 as the housekeeping gene. The ΔΔCt was calculated using a linear mixed model approach with gene x group interaction as the parameter of interest, adjusting for age, BMI and menopausal status, and considering random intercept and random slope terms to account for individual variability.

Results

No differences in EVs size and concentration among the four groups were detected. Considering the early BC group, the clinical stage at diagnosis and tumor subtype did not influence miR-21 expression. Higher expression of miR-21 has been found in metastatic versus healthy controls (p= 0.029 95% CI -1.549 to -0.079), mainly in HER2+ and hormone receptor positive patients (p 0.0005 and 0.036, respectively). In particular, in HER2+ miR-21 was significantly higher in patients with active BC (early and metastatic) (p 0.002 95% CI -1,707 to -0,376) compared to control group.

Conclusions

While further investigations shall be requested, our data on serum EV suggest that miR-21 may become a promising biomarker for early diagnosis and tumor activity, mainly in HER2+ BC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Claudia Omarini.

Funding

MIUR Dipartimenti Eccellenti 2022.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.